Processa Pharmaceuticals’ Dr. David Young to Present at World Orphan Drug Congress USA 2025

Rhea-AI Summary

Processa Pharmaceuticals (Nasdaq: PCSA) has announced that Dr. David Young, Founder and President of Research & Development, will present at the World Orphan Drug Congress USA 2025 in Boston. The presentation, scheduled for April 24, 2025, at 2:00 p.m. ET, will focus on 'Applying Principles of FDA's Project Optimus to Oncology and Non-Oncology Rare Diseases'.

Dr. Young will discuss how Project Optimus principles can be utilized to determine optimal dosing for improved efficacy and safety in rare disease treatments, both oncological and non-oncological. This approach aligns with Processa's Regulatory Science strategy, which aims to enhance therapeutic outcomes through improved regulatory science methodologies.

HANOVER, Md., April 15, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and safety, today announced that Dr. David Young, Founder and President of Research & Development, has been invited to present at the World Orphan Drug Congress USA 2025.

Dr. Young’s presentation, titled “Applying Principles of FDA’s Project Optimus to Oncology and Non-Oncology Rare Diseases,” will take place on Tuesday, April 24, 2025, at 2:00 p.m. Eastern Time at the Boston Convention & Exhibition Center.

Dr. Young’s presentation will explore how the principles of FDA’s Project Optimus initiative — particularly determining the optimal dose to improve the balance of efficacy and safety — can be used for the FDA approval of drugs to treat rare oncology and rare non-oncology diseases. This approach is core to Processa’s Regulatory Science approach, which focuses on improving therapies through regulatory science to deliver better outcomes for patients.

For more information about World Orphan Drug Congress USA 2025, please click here.

About Processa Pharmaceuticals, Inc.

Processa is a clinical-stage pharmaceutical company focused on developing the Next Generation Cancer (NGC) drugs with improved safety and efficacy. Processa’s NGC drugs are modifications of existing FDA-approved oncology therapies resulting in an alteration of the metabolism and/or distribution of these drugs while maintaining the existing mechanisms of killing the cancer cells. By combining its novel oncology pipeline with proven cancer-killing active molecules and its Regulatory Science Approach, Processa’s strategy is to develop more effective therapy options with improved tolerability for cancer patients through an efficient regulatory path.

For more information, visit our website at www.processapharma.com.

Company Contact:
Patrick Lin
(925) 683-3218
plin@processapharma.com

FAQ

When is Dr. David Young presenting at the World Orphan Drug Congress USA 2025 for PCSA?

Dr. Young will present on Tuesday, April 24, 2025, at 2:00 p.m. Eastern Time at the Boston Convention & Exhibition Center.

What is the topic of Processa Pharmaceuticals' (PCSA) presentation at the 2025 World Orphan Drug Congress?

The presentation is titled 'Applying Principles of FDA's Project Optimus to Oncology and Non-Oncology Rare Diseases.'

How does PCSA's presentation align with their company strategy?

The presentation aligns with Processa's Regulatory Science approach, which focuses on improving therapies through regulatory science to deliver better patient outcomes.

What is the main focus of Processa Pharmaceuticals' (PCSA) research and development?

PCSA is a clinical-stage pharmaceutical company focused on developing next generation cancer therapies with improved efficacy and safety.

Where will PCSA's presentation at the World Orphan Drug Congress 2025 take place?

The presentation will take place at the Boston Convention & Exhibition Center.